It regulates medicines, medical devices, clinical trials and other health products and monitors the safety of cosmetics.
[1] The Irish Medicines Board suspended Nimesulide from the Irish market and referred it to the EU Committee for Human Medicinal Products for a review of its benefit/risk profile due to the reporting of six cases of potentially-related liver failures by the National Liver Transplant Unit at St. Vincent's University Hospital between 1999 and 2006.
[2] In July 2018 the authority recalled a number of medicines containing the active ingredient Valsartan when an impurity was identified in a valsartan active substance manufactured at a facility in China.
[3] It produced a report on medicinal cannabis in 2018 which suggested a controlled access programme for cannabis products that are not capable of being authorized as a medicinal product.
[4] In 2017 it confiscated large quantities of counterfeit “high-end” beauty products, some of which were found to contain arsenic and lead.